2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (Updating the 2005 Guideline)

ACCF/AHA Task Force on Practice Guidelines. Methodologies andPolicies from the ACCF/AHA Task Force on Practice Guideline. Available at http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf and http://circ.ahajournals.org/site/manual/index.xhtml. Accessed July 1, 2011.

Hirsch AT Haskal ZJ Hertzer NR . ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary: a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). Circulation. 2006;113:1474–547.

Norgren L Hiatt WR Dormandy JA . Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33 Suppl 1:S1–75.

Hirsch AT Haskal ZJ Hertzer NR . ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). Circulation. 2006;113:e463–654.

Wheatley K Ives N Gray R . Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med. 2009;361:1953–62.

Cooper CJ Murphy TP Matsumoto A . Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. Am Heart J. 2006;152:59–66.

Alhadad A Mattiasson I Ivancev K . Revascularisation of renal artery stenosis caused by fibromuscular dysplasia: effects on blood pressure during 7-year follow-up are influenced by duration of hypertension and branch artery stenosis. J Hum Hypertens. 2005;19:761–7.

Modrall JG Rosero EB Smith ST . Operative mortality for renal artery bypass in the United States: results from the National Inpatient Sample. J Vasc Surg. 2008;48:317–22.

Criqui MH Denenberg JO Bird CE . The correlation between symptoms and non-invasive test results in patients referred for peripheral arterial disease testing. Vasc Med. 1996;1:65–71.

Hirsch AT Criqui MH Treat-Jacobson D . Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317–24.

Diehm C Allenberg JR Pittrow D . Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation. 2009;120:2053–61.

Fowkes FG . The measurement of atherosclerotic peripheral arterial disease in epidemiological surveys. Int J Epidemiol. 1988;17:248–54.

Feigelson HS Criqui MH Fronek A . Screening for peripheral arterial disease: the sensitivity, specificity, and predictive value of noninvasive tests in a defined population. Am J Epidemiol. 1994;140:526–34.

Nassoura ZE Ivatury RR Simon RJ . A reassessment of Doppler pressure indices in the detection of arterial lesions inproximity penetrating injuries of extremities: a prospective study. Am J Emerg Med. 1996;14:151–6.

Carter SA . Clinical measurement of systolic pressures in limbs with arterial occlusive disease. JAMA. 1969;207:1869–74.

Carter SA Tate RB . Value of toe pulse waves in addition to systolic pressures in the assessment of the severity of peripheral arterial disease and critical limb ischemia. J Vasc Surg. 1996;24:258–65.

Carter SA Tate RB . The value of toe pulse waves in determination of risks for limb amputation and death in patients with peripheral arterial disease and skin ulcers or gangrene. J Vasc Surg. 2001;33:708–14.

Brooks B Dean R Patel S . TBI or not TBI: that is the question: is it better to measure toe pressure than ankle pressure in diabetic patients? Diabet Med. 2001;18:528–32.

Ramsey DE Manke DA Sumner DS . Toe blood pressure: a valuable adjunct to ankle pressure measurement for assessing peripheral arterial disease. J Cardiovasc Surg (Torino). 1983;24:43–8.

Belcaro G Nicolaides AN Bull ML . The value of segmental pressure measurement in the assessment of peripheral vascular disease. Int Angiol. 1986;5:7–12.

Gundersen J . Segmental measurements of systolic blood pressure in the extremities including the thumb and the great toe. Acta Chir Scand Suppl. 1972;426:1–90.

Johnston KW Hosang MY Andrews DF . Reproducibility of noninvasive vascular laboratory measurements of the peripheral circulation. J Vasc Surg. 1987;6:147–51.

Kupinski A . Segmental pressure measurement and plethysmography. J Vasc Technol. 2002;1:32–8.

Fowkes FG Murray GD Butcher I . Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300:197–208.

Nides MA Rakos RF Gonzales D . Predictors of initial smoking cessation and relapse through the first 2 years of the Lung Health Study. J Consult Clin Psychol. 1995;63:60–9.

Mohiuddin SM Mooss AN Hunter CB . Intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease. Chest. 2007;131:446–52.

Lancaster T Stead LF . Mecamylamine (a nicotine antagonist) for smoking cessation. Cochrane Database Syst Rev. 2000;CD001009.

Rothemich SF Woolf SH Johnson RE . Effect on cessation counseling of documenting smoking status as a routine vital sign: an ACORN study. Ann Fam Med. 2008;6:60–8.

Hennrikus D Joseph A Lando H . Effectiveness of a smoking cessation program for peripheral artery disease patients: a randomized controlled trial. JACC. 2010;25:2105–12.

Gonzales D Rennard SI Nides M . Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47–55.

Jorenby DE Hays JT Rigotti NA . Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56–63.

Nides M Oncken C Gonzales D . Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med. 2006;166:1561–8.

Jorenby DE Leischow SJ Nides MA . A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685–91.

Faulkner KW House AK Castleden WM . The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease. Med J Aust. 1983;1:217–9.

Jonason T Bergstrom R . Cessation of smoking in patients with intermittent claudication: effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand. 1987;221:253–60.

Lassila R Lepantalo M . Cigarette smoking and the outcome after lower limb arterial surgery. Acta Chir Scand. 1988;154:635–40.

Quick CR Cotton LT . The measured effect of stopping smoking on intermittent claudication. Br J Surg. 1982;69 Suppl:S24–6.

Gardner AW . The effect of cigarette smoking on exercise capacity in patients with intermittent claudication. Vasc Med. 1996;1:181–6.

Law M Tang JL . An analysis of the effectiveness of interventions intended to help people stop smoking. Arch Intern Med. 1995;155:1933–41.

West R Baker CL Cappelleri JC . Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology (Berl). 2008;197:371–7.

Knight C Howard P Baker CL . The cost-effectiveness of an extended course (12+12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model. Value Health. 2010;13:209–14.

Olin JW . Thromboangiitis obliterans (Buerger’s disease). N Engl J Med. 2000;343:864–9.

CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–39.

Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [published correction appears in BMJ. 2002;324:141]. BMJ. 2002;324:71–86.

Catalano M Born G Peto R . Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med. 2007;261:276–84.

Belch J MacCuish A Campbell I . The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.

Fowkes FG Price JF Stewart MC . Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303:841–8.

Bhatt DL Fox KA Hacke W . Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–17.

Cacoub PP Bhatt DL Steg PG . Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2009;30:192–201.

Anand S Yusuf S Xie C . Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007;357:217–27.

Berger JS Krantz MJ Kittelson JM . Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA. 2009;301:1909–19.

Bhatt DL Flather MD Hacke W . Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49:1982–8.

Bernstein EF Rhodes GA Stuart SH . Toe pulse reappearance time in prediction of aortofemoral bypass success. Ann Surg. 1981;193:201–5.

Bradbury AW Adam DJ Bell J . Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: an intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy. J Vasc Surg. 2010;51:5S–17S.

Adam DJ Beard JD Cleveland T . Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005;366:1925–34.

Greenhalgh RM Brown LC Powell JT . Endovascular versus open repair of abdominal aortic aneurysm. N Engl J Med. 2010;362:1863–71.

Blankensteijn JD de Jong SE Prinssen M . Two-year outcomes after conventional or endovascular repair of abdominal aortic aneurysms. N Engl J Med. 2005;352:2398–405.

De Bruin JL Baas AF Buth J . Long-term outcome of open or endovascular repair of abdominal aortic aneurysm. N Engl J Med. 2010;362:1881–9.

Greenhalgh RM Brown LC Powell JT . Endovascular repair of aortic aneurysm in patients physically ineligible for open repair. N Engl J Med. 2010;362:1872–80.

Lederle FA Freischlag JA Kyriakides TC . Outcomes following endovascular vs open repair of abdominal aortic aneurysm: a randomized trial. JAMA. 2009;302:1535–42.

Brown LC Epstein D Manca A . The UK Endovascular Aneurysm Repair (EVAR) trials: design, methodology and progress. Eur J Vasc Endovasc Surg. 2004;27:372–81.

Schanzer A Hevelone N Owens CD . Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia. J Vasc Surg. 2008;47:774–81.

Conte MS Bandyk DF Clowes AW . Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg. 2006;43:742–51.

Diehm C Schuster A Allenberg JR . High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis. 2004;172:95–105.

Hennrikus D Joseph AM Lando HA . Effectiveness of a smoking cessation program for peripheral artery disease patients: a randomized controlled trial. J Am Coll Cardiol. 2010;56:2105–12.

Bhatt DL Topol EJ . Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J. 2004;148:263–8.